Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06003426 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

A Phase 3 study of Idiopathic Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
1,255
Enrollment target
20
Study locations

NCT06003426 is a Phase 3 study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 1,255 participants, above the 727-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (73% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06003426, a Phase 3 study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
1,255 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Conditions Studied

Idiopathic Pulmonary Fibrosis

Interventions

  • DRUG BMS-986278
  • DRUG BMS-986278 Placebo

Study Locations (20)

California

  • Local Institution - 0396 - La Jolla
  • Local Institution - 0193 - Los Angeles
  • Local Institution - 0398 - Los Angeles
  • Local Institution - 0389 - Orange
  • Local Institution - 0405 - Sacramento
  • Local Institution - 0185 - San Francisco
  • Local Institution - 0186 - Stanford

Florida

  • Local Institution - 0101 - Brandon
  • Local Institution - 0436 - Clearwater
  • Local Institution - 0425 - DeBary
  • Local Institution - 0079 - Gainesville
  • Local Institution - 0352 - Hialeah
  • Local Institution - 0370 - Kissimmee

Colorado

  • Local Institution - 0363 - Aurora
  • Local Institution - 0194 - Denver

Alabama

  • Local Institution - 0189 - Birmingham

Arizona

  • Local Institution - 0361 - Phoenix

Connecticut

  • Local Institution - 0175 - New Haven

Delaware

  • Local Institution - 0151 - Newark

District of Columbia

  • Local Institution - 0367 - Washington D.C.

Trial Details

FieldValue
Enrollment Target 1,255 participants
Start Date 2023-09-14
Est. Completion 2026-10-26
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06003426

The ClinicalTrials.gov registry entry for NCT06003426 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,255 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 727-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (73% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986278 is the first listed.

NCT06003426 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Colorado.

Frequently Asked Questions

What is clinical trial NCT06003426 about?

NCT06003426 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis". The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

What is the current status of trial NCT06003426?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,255 participants. The study started on 2023-09-14. Estimated completion is 2026-10-26.

What conditions does trial NCT06003426 study?

This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.

What interventions are being tested in trial NCT06003426?

The interventions under investigation include: BMS-986278 (DRUG), BMS-986278 Placebo (DRUG).

Who is sponsoring clinical trial NCT06003426?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06003426 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Idiopathic Pulmonary Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Idiopathic Pulmonary Fibrosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.